KR930703449A - 융합 ms-2 코트 단백질을 포함하는 항원-제공 캡시드 - Google Patents

융합 ms-2 코트 단백질을 포함하는 항원-제공 캡시드

Info

Publication number
KR930703449A
KR930703449A KR1019930702199A KR930702199A KR930703449A KR 930703449 A KR930703449 A KR 930703449A KR 1019930702199 A KR1019930702199 A KR 1019930702199A KR 930702199 A KR930702199 A KR 930702199A KR 930703449 A KR930703449 A KR 930703449A
Authority
KR
South Korea
Prior art keywords
protein
capsid
coat protein
amino acid
chimeric protein
Prior art date
Application number
KR1019930702199A
Other languages
English (en)
Other versions
KR100197819B1 (ko
Inventor
알란 마스티코 로버트
죠오지 스톡클리 피터
죤 탈보트 시몬
Original Assignee
디 알 챤들러
브리티쉬 테크놀로지 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디 알 챤들러, 브리티쉬 테크놀로지 그룹 리미티드 filed Critical 디 알 챤들러
Publication of KR930703449A publication Critical patent/KR930703449A/ko
Application granted granted Critical
Publication of KR100197819B1 publication Critical patent/KR100197819B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)

Abstract

본 발명은 키메라 단백질에 관한 것으로, 이 단백질은 백신에의 통합에 적당하며 캡시드 어셈블리의 일부분을 형성할 수 있고, 파지 MS-2의 코트 단백질의 아미노산 서열, 또는 그것의 보존적으로 변형된 변이체, 또는 캡시드-형성 능력을 보유하기에 충분한 상기 서열의 단편 또는 변이체를 포함하며, 상기 아미노산 서열은 무상 파지의 결정구조에서 볼 수 있는 바와같이 캡시드 어셈블리의 용기 단백질 헤어핀 구조에 상응하는 영역에 의해 에피토프를 삽입함으로써 변형되었다.

Description

융합 MS-2 코트 단백질을 포함하는 항원-제공 캡시드
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 SDS-PAGE및 웨스턴 블롯에 의한 카메라 MS-2 단백질을 확인하는 도면, 제2도는 야생형 MS-2에 대한 전자 현미경 사진, 제3도는 MS2-캡시드에 대한 전자 현미경 사진.

Claims (11)

  1. 캡시드 어셈블리의 일부분을 형성할 수 있고, 파지 MS-2의 코트 단백질의 아미노산 서열 또는 그것의 보존적으로 변형된 변이체, 또는 캡시드-형성 능력을 보유하기에 충분한 상기 서열의 단편 또는 변이체를 포함하는 키메라 단백질로서, 상기 아미노산 서열은 코트 단백질의 N-말단 융기 b-헤어핀 구조에 해당하는 영역에 외래 에피토프를 삽입시킴으로써 변형된 것을 특징으로 하는 키메라 단백질.
  2. 제1항에 있어서, 파지 MS-2의 코트 단백질의 아미노산 서열을 포함하는 키메라 단백질.
  3. 제1항 또는 2항에 있어서, 외래 에피토프는 MS-2의 코트 단백질 서열에 관련하여 아미노산 잔기 1내지 20의 영역에 삽입된 것을 특징으로 하는 키메라 단백질.
  4. 제3항에 있어서, 외래 에피토프가 글리신 14와 트레오닌 15의 영역에 삽입된 것을 특징으로 하는 키메라 단백질.
  5. 전술한 항중 어느 한 항에 있어서, 외래 에피토프 바로 위쪽 및 아래쪽 영역에 하나 또는 그 이상의 글리신 잔기를 포함하는 키메라 단백질.
  6. 전술한 항중 어느 한 항의 키메라 단백질 또는 이러한 단백질들의 혼합물을 포함하는 캡시드.
  7. 제1항 내지 5항중 어느 한 항의 키메라 단백질의 또는 제6항의 캡시드의 제조방법으로서, MS-2의 코트단백질에 상응하는 cDNA서열, 또는 이러한 코트 단백질의 보존적으로 변형된 변이체 또는 캡시드-형성 능력을 보유하기에 충분한 상기 단백질의 단편 또는 변이체에 상응하는 cDNA서열을, 부위 특정 돌연별이 생성에 적당한 서열화 벡터에 도입시키는 단계, 융기 헤어핀 구조를 코드하는 cDNA의 영역에 독특한 제한효소 인지 부위를 생성시키는 단계, 외래 에피토프를 포함하고 있는 올리고누클레오티드를 제한부위에 도입시키고, 하위 클로닝함으로써 변형된 유전자를 적당한 발현벡터안에 도입시키는 단계, 그리고 적당한 숙주에서 외래 유전자를 내포하는 변형된 발현 벡터로 부터의 발현을 유도하는 단계로 이루어지는 방법.
  8. 제7항에 있어서, 숙주가 대장균임을 특징으로 하는 방법.
  9. 제1항 내지 6항중 어느 한 항의 키메라 단백질을 코드하는 DNA를 포함하는 발현벡터.
  10. 제9항의 발현벡터에 의해 형질전환된 숙주.
  11. 제1항 내지 5항중 어느 한 항의 단백질 또는 제 6항의 캡시드를 포함하는 백신제제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930702199A 1991-01-24 1992-01-22 융합 ms2 코트 단백질을 포함하는 항원제공 캡시드 KR100197819B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB910550.3 1991-01-24
GB919101550A GB9101550D0 (en) 1991-01-24 1991-01-24 Antigen-presenting chimaeric protein
PCT/GB1992/000124 WO1992013081A1 (en) 1991-01-24 1992-01-22 Antigen-presenting capsid with fusion ms2-coat protein

Publications (2)

Publication Number Publication Date
KR930703449A true KR930703449A (ko) 1993-11-30
KR100197819B1 KR100197819B1 (ko) 1999-06-15

Family

ID=10688936

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930702199A KR100197819B1 (ko) 1991-01-24 1992-01-22 융합 ms2 코트 단백질을 포함하는 항원제공 캡시드

Country Status (15)

Country Link
US (1) US5534257A (ko)
EP (1) EP0572433B1 (ko)
JP (1) JP3187832B2 (ko)
KR (1) KR100197819B1 (ko)
AT (1) ATE201449T1 (ko)
AU (1) AU653387B2 (ko)
CA (1) CA2101070C (ko)
DE (1) DE69231837T8 (ko)
FI (1) FI110615B (ko)
GB (2) GB9101550D0 (ko)
IE (1) IE920200A1 (ko)
NO (1) NO313917B1 (ko)
NZ (1) NZ241373A (ko)
WO (1) WO1992013081A1 (ko)
ZA (1) ZA92511B (ko)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9114003D0 (en) * 1991-06-28 1991-08-14 Mastico Robert A Chimaeric protein
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
WO1995005454A1 (en) * 1992-02-22 1995-02-23 Cambridge Bacteriophage Technologies Ltd. Engineered bacteriophages and vaccines containing them
GB9213601D0 (en) * 1992-06-26 1992-08-12 Mastico Robert A Protein based delivery system
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
JP3421970B2 (ja) 1996-03-01 2003-06-30 ノバルティス アクチエンゲゼルシャフト ペプチド免疫原
US5766905A (en) * 1996-06-14 1998-06-16 Associated Universities Inc. Cytoplasmic bacteriophage display system
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
IL140918A0 (en) 1998-07-27 2002-02-10 Genentech Inc Improved transformation efficiency in phage display through modification of a coat protein
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
JP2003516755A (ja) * 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
MXPA04002644A (es) 2001-10-05 2004-07-08 Cytos Biotechnology Ag Conjugados que portan un peptido de angiotensina y usos de los mismos.
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
JP4495587B2 (ja) 2002-04-25 2010-07-07 クルセル ホランド ベー ヴェー 組換えアデノウイルスベクターおよびその使用
NZ537003A (en) 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
WO2004016282A1 (en) 2002-07-19 2004-02-26 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
WO2004084940A1 (en) 2003-03-26 2004-10-07 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
AU2005250369A1 (en) * 2004-05-18 2005-12-15 Genentech, Inc. M13 virus major coat protein variants for C-terminal and BI-terminal display of a heterologous protein
EP1812051A2 (en) * 2004-10-05 2007-08-01 Cytos Biotechnology AG Vlp-antigen conjugates and their uses as vaccines
EP1746165A1 (en) * 2005-07-21 2007-01-24 Cytos Biotechnology AG Scalable fermentation process
CN101213294B (zh) * 2005-05-26 2013-03-27 赛托斯生物技术公司 可放大的发酵方法
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
EP2431468A1 (en) 2005-09-28 2012-03-21 Cytos Biotechnology AG Interleukin-1 conjugates and uses thereof
EP1973608A1 (en) 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
WO2007084568A2 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
SG172696A1 (en) 2006-06-12 2011-07-28 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
EP2554664A1 (de) 2011-08-02 2013-02-06 Life Science Inkubator Verfahren zur Aufreinigung von Virus-ähnlichen Partikeln (VLP)
RU2568872C1 (ru) * 2014-10-15 2015-11-20 Игорь Геннадьевич Сивов Лекарственное средство для лечения вирусного гепатита с
WO2021215952A1 (ru) 2020-04-24 2021-10-28 Общество С Ограниченной Ответственностью "Индженик" Способ получения частиц бактериофагов семейства levivirus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU637049B2 (en) * 1988-05-05 1993-05-20 American Cyanamid Company Recombinant flagellin vaccines
IT1226551B (it) * 1988-07-29 1991-01-24 Sclavo Spa Peptide sintetico immunologicamente attivo capace di indurre la produzione di anticorpi con elevata specificita' verso l'alfa- fetoproteina e loro impiego in campo diagnostico
AU629237B2 (en) * 1988-08-30 1992-10-01 Applied Research Systems Ars Holding N.V. Recombinant fusion proteins for altering hormone secretion
WO1990014355A1 (en) * 1989-05-17 1990-11-29 Research Corporation Technologies, Inc. Retrovirus-mediated secretion of recombinant products

Also Published As

Publication number Publication date
JPH06504907A (ja) 1994-06-09
ATE201449T1 (de) 2001-06-15
CA2101070C (en) 2003-04-01
EP0572433A1 (en) 1993-12-08
AU1173792A (en) 1992-08-27
US5534257A (en) 1996-07-09
GB2253626B (en) 1995-02-08
GB9201372D0 (en) 1992-03-11
GB2253626A (en) 1992-09-16
DE69231837T2 (de) 2001-10-18
NZ241373A (en) 1993-04-28
FI110615B (fi) 2003-02-28
ZA92511B (en) 1992-11-25
DE69231837T8 (de) 2004-08-12
NO313917B1 (no) 2002-12-23
IE920200A1 (en) 1992-07-29
GB9101550D0 (en) 1991-03-06
NO932644L (no) 1993-09-23
CA2101070A1 (en) 1992-07-25
DE69231837D1 (de) 2001-06-28
JP3187832B2 (ja) 2001-07-16
FI933328A0 (fi) 1993-07-23
EP0572433B1 (en) 2001-05-23
KR100197819B1 (ko) 1999-06-15
NO932644D0 (no) 1993-07-22
WO1992013081A1 (en) 1992-08-06
AU653387B2 (en) 1994-09-29
FI933328A (fi) 1993-09-07

Similar Documents

Publication Publication Date Title
KR930703449A (ko) 융합 ms-2 코트 단백질을 포함하는 항원-제공 캡시드
AR018603A1 (es) Un peptido, util para el tratamiento y/o profilaxis de la enfermedad de alzheimer y el sindrome de down, las composiciones farmaceuticas y vacunas que locontienen, el uso de dicho peptido para la preparacion de las composiciones farmaceuticas, una secuencia de aislado de adn, un plasmido o vector vi
DK263689A (da) Modificeret baculovirus, fremgangsmaade til dets fremstilling samt dets anvendelse som ekspressionsvektor for gener
NO179253C (no) Rekombinant DNA-sekvens som koder for humant proapolipoprotein A-I, ekspresjonsvektorer, cellekulturer samt fremgangsmåte for fremstilling av proteinet
ATE64619T1 (de) Menschliches apolipoprotein a1 sowie dessen variante, exprimiert in escherichia coli.
EA199800973A1 (ru) Полипептид белка-106 наружной мембраны moraxella catarrhalis, последовательность гена и их применение
EP1190043A4 (en) GLYCOPROTEIN VI AND ITS USES
KR880007734A (ko) 폴리펩타이드 유도체
CA2180103A1 (en) Gene encoding adseverin
RU93045577A (ru) Слитные полипептиды
DK0562508T3 (da) Nyt knogle-relateret protein OSF-2, fremgangsmåde til dets fremstilling samt farmaceutisk præparat med indhold deraf
Wang et al. Heavy-chain variable regions in normal and pathological immunoglobulins
KR920012440A (ko) 인간 인터류킨-5 수용체
ATE327321T1 (de) Zyklische depsipeptid-synthasen, deren gene und system zur massenproduktion von zyklischen depsipeptiden
KR930000684A (ko) 클로닝된 글루탐산 탈탄산효소
DK312787D0 (da) Polypeptider, fremgangsmaade til deres fremstilling, dna som koder for polypeptiderne, vektorer indeholdende saadanne gensekvenser og laegemidler indeholdende polypeptiderne
WO2002016589A3 (en) Human abc transporter family member and uses thereof
KR970059279A (ko) 헬리코박터 파이로리의 외막단백질(Omp22) 유전자 및 그를 발현하는 재조합 미생물
SE9503379D0 (sv) A modified GAD, a method for producing a modified GAD, a method for supplying a modified GAD, a peptide and the use of an ordinary and/or a modified GAD
DE60135650D1 (de) Amidotransferase und dessen expressionsprodukt
ATE116687T1 (de) Stamm ral-4, nützlich zur herstellung kleiner proteine und peptide.
Hirabayashi et al. Arginine-tail method, an affinity tag procedure utilizing anhydrotrypsin agarose
EP0845536A3 (en) Protein having ethylenediamine-N,N'-disuccinic acid: ethylenediamine lyase activity and gene encoding the same
HU903490D0 (en) Process for the preparation of proteins, vaccines and nucleic acid
EP1568775A4 (en) CANCER ASSOCIATED GEN

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20040826

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee